Semaglutide

Semaglutide is a synthetic peptide that mimics glucagon-like peptide-1, a hormone the gut releases after eating. It became one of the most widely used peptides in the world after pharmaceutical formulations — sold under brand names like Ozempic and Wegovy — gained regulatory approval for blood-sugar management and weight management.

In a research and personal-logging context, semaglutide is almost always supplied as a lyophilized white powder inside a small glass vial, rated in milligrams of active peptide. The vial has to be reconstituted with bacteriostatic water before any volume can be drawn into a syringe. Common vial sizes seen in the research market range from 2 mg up to 10 mg or larger.

Because semaglutide is long-acting — its half-life is roughly a week — it is typically logged on a weekly cadence. That single property shapes everything about how the peptide is dosed, how often a vial is opened, and how vial duration is calculated for refill planning.

A defining characteristic of Semaglutide is its extended half-life, which is documented in research literature to be approximately seven days. This pharmacokinetic property is the foundation upon which weekly administration schedules are built. Unlike peptides with shorter half-lives that require more frequent administration to maintain stable levels, a single weekly dose of Semaglutide is sufficient to sustain its presence over the subsequent week. Understanding this principle is fundamental to planning a personal tracking strategy, as it directly influences how concentrations accumulate over time and why observations may evolve over the initial weeks of a schedule.

Another critical concept for personal documentation is the titration schedule, a common feature in published Semaglutide studies. These protocols typically do not start at a target dose but instead begin with a smaller initial dose that is incrementally increased over a period of weeks or months. For anyone logging their experience, this dose escalation is the most significant variable to document accurately. Recording the precise date and magnitude of each step-up is essential for any meaningful retrospective analysis of logged data correlated against dose levels.

GLP-1 agonists bind to receptors in the pancreas and the brain. Activating the pancreatic receptor influences insulin and glucagon release in response to glucose; activating the central receptor influences appetite and gastric emptying. Semaglutide is engineered to resist enzymatic breakdown, which is what gives it its long half-life relative to native GLP-1.

Researchers and individuals tracking semaglutide are usually looking at weekly weight, hunger ratings, blood sugar readings, and side-effect notes alongside the dose log itself. Pairing those metrics with the dose history is how patterns become visible — for example, whether a dose change correlated with a change in hunger ratings the following week.

The ~7-day half-life mathematically dictates how Semaglutide accumulates in the body to reach a steady-state concentration. After the first weekly dose, approximately 50% of the peptide remains after seven days, at which point the second dose is administered. This new dose adds to the remaining concentration from the first. This stacking process continues with each subsequent weekly administration, with the total amount of the peptide present in the body incrementally increasing. After approximately four to five half-lives, or four to five weeks, the amount being eliminated over the week becomes roughly equal to the amount being added, establishing a concentration plateau known as steady state. This dynamic explains why logged observations during the first month may differ from those documented once this plateau is reached.

Weekly dosing is the default cadence for semaglutide because of its long half-life. Each injection is a small subcutaneous draw, almost always measured on a U-100 insulin syringe rather than a tuberculin syringe, because the volumes involved are very small.

Many semaglutide protocols start with a low weekly dose and escalate gradually over several weeks or months to reduce gastrointestinal side effects. Tracking that escalation accurately is one of the main reasons people move away from notes apps and toward a structured dose log: the cumulative pattern over months is what matters, and a pattern is hard to read from scattered text notes.

Skipped or delayed doses are recorded as deliberately as taken doses in most well-run logs, because gaps in the schedule meaningfully change the next week's planning. A vial-aware tracker also flags when the current vial is approaching empty so the next vial can be ordered in time, given semaglutide's typical four-to-six-week shipping windows.

When individuals plan to document a titration schedule observed in research studies, the core logging task becomes tracking the dose changes. A typical study protocol might involve starting at a low dose and stepping up that dose every four weeks. From a data-logging perspective, the calendar dates of these transitions are the most pivotal entries. Without a clear record of when the dose was increased from 0.25 mg to 0.5 mg, for example, it becomes impossible to later parse subjective or objective data and accurately attribute it to a specific dosage period. Therefore, a robust log must cleanly delineate each dosing chapter defined by the titration points.

Semaglutide vials commonly arrive at 2 mg, 5 mg, or 10 mg. The illustrative example on this page assumes a 5 mg vial reconstituted with 2 mL of bacteriostatic water, producing a concentration of 2.5 mg per mL. A 0.25 mg dose on that vial is 0.1 mL — exactly 10 units on a U-100 insulin syringe.

Because typical semaglutide doses are small relative to the vial, choosing a sensible diluent volume matters. Using 1 mL of BAC water on a 5 mg vial concentrates the solution and makes each draw a tiny number of units, which is harder to read accurately on the syringe. Using 3 mL spreads the dose over a larger volume and produces cleaner unit counts at the cost of slightly fewer total doses per vial.

A frequent point of confusion during a titration schedule is the relationship between dose mass (mcg), solution volume (mL), and syringe units. The concentration of the reconstituted vial is constant; for example, a 5 mg vial reconstituted with 2 mL results in a fixed concentration of 2,500 mcg/mL. However, the dose in mass changes with each titration step. A 0.25 mg illustrative dose is 250 mcg, which corresponds to a volume of 0.1 mL or 10 units on a U-100 syringe. When the schedule steps up to a 0.5 mg dose (500 mcg), the volume drawn must double to 0.2 mL or 20 units, even though the vial’s concentration has not changed. Accurately calculating the new volume for each dose increase is a crucial step for adhering to a planned schedule.

Lyophilized semaglutide powder is generally stored refrigerated until reconstitution. Once reconstituted with bacteriostatic water, the in-use vial is typically kept refrigerated and used within four to six weeks. Writing the reconstitution date directly on the vial is one of the simplest ways to avoid running a long-opened vial past its useful life.

Light exposure and repeated temperature cycling both reduce stability. Storing the vial in the door of a refrigerator — where temperature swings most each time the door opens — is a common avoidable mistake.

Tracking semaglutide well means linking each dose log entry to the specific vial it came from, so the unit count on the syringe always reflects that vial's actual concentration. When a vial is finished and a new one is set up, the new vial's reconstitution numbers replace the old ones automatically — no muscle memory carries over from the prior vial.

Pairing the dose log with weekly weight and weekly hunger ratings turns a list of injections into a real signal. Peptide Pilot was built around exactly this pattern: log the dose, log the metric, and let the app surface the trend over weeks rather than asking you to scroll through note entries.

For sophisticated personal tracking of a multi-step Semaglutide protocol, logging should go beyond simple weekly dose entries. The most effective method is to create a distinct milestone entry in the log for each titration event. This means specifically documenting, for instance, 'Titration to 0.5 mg' on the exact date it occurs. This approach structures the entire data set, allowing a user to later filter and analyze all subsequent observations—such as body weight, food intake, or side effects—based on the active dose period. This turns a simple timeline into a structured database, where one can isolate and observe the body's response during the '0.25 mg phase' versus the '0.5 mg phase,' providing clarity that a flat log cannot.